Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ZM-02-L, ZM-02-H, ZM-02-S.
- Who it may be relevant to
- Registry conditions: Retinitis Pigmentosa. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of ZM-02 in Retinitis Pigmentosa
Overview
This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.
Detailed description
Retinitis pigmentosa (RP) is the most common inherited retinal disease. Individuals affected by RP often experience progressive visual impairment, potentially leading to legal blindness. There is currently no established effective clinical treatment available. We developed an innovative adeno-associated virus (AAV)-based gene therapy for individuals with RP, regardless of their causative mutations. Eight to twelve subjects with RP will be recruited and six to nine of them will receive a single unilateral intravitreal injection of ZM-02 at ascending doses, while two to three receive sham injections as the control group.
Interventions
- Drug ZM-02-L
rAAV-PsCatCh2.0 intravitreal injection of low dose - Drug ZM-02-H
rAAV-PsCatCh2.0 intravitreal injection of high dose - Procedure ZM-02-S
sham intravitreal injection of ZM-02 (not actual injection)
Primary outcome measures
- Incidence of adverse events and serious adverse events [Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52]
- Changes in intraocular pressure (IOP) in Subjects [Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52]
Secondary outcome measures (3)
- Change of MLMT level [Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52]
- Change of Quality of Life [Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52]
- Change in best corrected visual acuity (BCVA) [Time frame: baseline to day 3, week 1, 4, 12, 24, 36, 52]
Eligibility criteria
Inclusion criteria
Patients who meet all of the following criteria can be selected as subjects:
- Clinically diagnosed with retinal pigment degeneration
- The visual acuity of study eye is no better than the finger counting, while the visual acuity of the study eye is not better than that of the contralateral eye
- The subject has had visual experience above the finger counting
- In the OCT examination of the tested eye, the disappearance of the ellipsoid zone is observed, but the inner nuclear layer and the nerve fiber layer of the retina are still present
- The refractive power of the tested eye is between -6.00 D and +6.00 D
- Not infected with the Human Immunodeficiency Virus (HIV) and other acute and chronic infectious diseases
- Voluntarily sign an Informed Consent Form (ICF), and the age is not less than 18 years and not more than 65 years
- Able to fully understand and agree to cooperate with the implementation of the research protocol
Exclusion criteria
Subjects who meet any one of the following exclusion criteria will be excluded from the study:
- Pregnant women, breastfeeding women, or male and female subjects who do not agree to contraception during the 12 months before and after medication
- Subjects with narrow anterior chamber angles or any other medical conditions that contraindicate pupil dilation
- Subjects allergic to corticosteroids, who are unable to tolerate the corticosteroid treatment described in the protocol, or have active 4. concurrent infections that contraindicate treatment
- Subjects with systemic diseases, or other medical or mental illnesses, or other safety concerns for the study
- Subjects with other symptoms and/or diseases or conditions that can alter visual function, including but not limited to glaucoma and central nervous system lesions (mild cataracts are not included in this restriction)
- Eye diseases that may interfere with the assessment of vision during the study and/or interfere with other ocular assessments such as OCT
- Diseases that may affect the clinical trial, such as tumors, metabolic, immune-related diseases, etc.
- Subjects who have undergone major eye surgery within the last 3 months before screening
- Subjects with a history of malignant tumors within the last 5 years
- Subjects with other retinal diseases not suitable for this study, such as retinal detachment
- Patients undergoing or potentially undergoing immunosuppressive treatment for other diseases, excluding this study
- Participation in any clinical trials other than this study within the last 3 months
- Subjects who have received gene therapy outside of this study
- Other reasons deemed by the researcher as unsuitable for participation in this study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Beijing Tongren Hospital of Capital Medical University — Beijing
Identifiers
NCT: NCT06292650 · MOON-01